Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Apple Restores Telegram to App Store After Content Policy Violation 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Jetstar to Charge for Overhead Cabin Bags From February 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
NEW YORK, April 02, 2018 -- Maxim Group LLC, a leading full service investment banking, securities and wealth management firm today announced the enhancement of its Healthcare Equity Research practice with the promotion of Dr. Jason McCarthy, Ph.D. to Senior Managing Director of Biotechnology.
“Maxim Group continues to build one of the premier proprietary research platforms on Wall Street, with an emphasis on emerging growth and paradigm-shifting businesses. Biotechnology is an important vertical in our healthcare practice and we are proud to have Jason leading this effort,” said Anthony V. Vendetti, Executive Managing Director of Research for Maxim Group. The biotechnology team currently covers over 50 research names and expects to double research coverage over the next year as more resources are added to build out this important vertical.
In his expanded role, Dr. McCarthy will work with Anthony Vendetti in the development and implementation of Maxim Group’s biotechnology research strategy with a key focus on product expansion on the Institutional and Wealth Management platforms. Dr. McCarthy received his doctoral degree in Biomedical Research (Albert Einstein College of Medicine) and Molecular Biology (Adelphi University), as well as a B.S. in Biochemistry from Stony Brook University.
Michael Rabinowitz, Chairman & CEO of Maxim Group, added “Our commitment to build a first class healthcare practice has never wavered, and Dr. McCarthy’s well-deserved promotion is another significant step in that process. As we continue our firm-wide expansion, we expect to add other high quality professionals to the Maxim Group Research team.”
About Maxim Group LLC
Maxim Group LLC is a full-service investment banking, securities and wealth management firm headquartered in New York. The Firm provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed-income and derivatives sales & trading, equity research and prime brokerage services to a diverse range of corporate clients, institutional investors and high net worth individuals. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission (SEC) and the Municipal Securities Rulemaking Board (MSRB), and is a member of the following: Financial Industry Regulatory Authority (FINRA); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and NYSE Arca, Inc. To learn more about Maxim Group, visit www.maximgrp.com.
For further information please contact:
John J. Garrity
Chief Marketing Officer
212.895.3624
[email protected]
